Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 23 Jan 2023

GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma

in Cancer Molecular Targets and Therapeutics

Nan Chen
Jieqing Wang
Lei Zhou
Baiqiang Hu
Yinzhong Chen
Zhuangchen Zhu

Frontiers in Oncology

doi 10.3389/fonc.2022.1113785

2,149 views
3 citations

Review

Published on 23 Jan 2023

Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade

in Cancer Molecular Targets and Therapeutics

Deborah Choe
Dongwon Choi

Frontiers in Oncology

doi 10.3389/fonc.2023.1088038

7,935 views
16 citations

Review

Published on 23 Jan 2023

COMMD proteins function and their regulating roles in tumors

in Cancer Molecular Targets and Therapeutics

Guangqiang You
Chen Zhou
Lei Wang
Zefeng Liu
He Fang
Xiaoxao Yao
Xuewen Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1067234

10,543 views
7 citations

Review

Published on 23 Jan 2023

Sulforaphane: An emergent anti-cancer stem cell agent

in Cancer Molecular Targets and Therapeutics

Leandro de Lima Coutinho
Tharcísio Citrangulo Tortelli Junior
Maria Cristina Rangel

Frontiers in Oncology

doi 10.3389/fonc.2023.1089115

29,988 views
26 citations

Original Research

Published on 20 Jan 2023

HROP68: A rare case of medullary pancreatic cancer—characterization and chemosensitivity of the first patient-derived cell line

in Cancer Molecular Targets and Therapeutics

Jens von den Driesch
Jana Flöttmann
Friedrich Prall
Christina S. Mullins
Michael Linnebacher
Florian Bürtin

Frontiers in Oncology

doi 10.3389/fonc.2022.1082927

2,628 views
4 citations

Original Research

Published on 20 Jan 2023

14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression

in Cancer Molecular Targets and Therapeutics

S. Breedy
W.S. Ratnayake
L. Lajmi
R. Hill
M. Acevedo-Duncan

Frontiers in Oncology

doi 10.3389/fonc.2023.1051516

2,849 views
2 citations

Review

Published on 19 Jan 2023

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

in Cancer Molecular Targets and Therapeutics

Hendrik Setia Budi
Laith A. Younus
Methaq Hadi Lafta
Sameena Parveen
Hawraa Jabbar Mohammad
Zahraa Haleem Al-qaim
Mohammed Abed Jawad
Rosario Mireya Romero Parra
Yasser Fakri Mustafa
Firas Rahi Alhachami

Frontiers in Oncology

doi 10.3389/fonc.2022.1067974

5,364 views
34 citations

Mini Review

Published on 19 Jan 2023

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

in Cancer Molecular Targets and Therapeutics

Kristina Aaltonen
Katarzyna Radke
Aleksandra Adamska
Alexandra Seger
Adriana Mañas
Daniel Bexell

Frontiers in Oncology

doi 10.3389/fonc.2022.1085270

5,503 views
12 citations

Original Research

Published on 18 Jan 2023

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

in Cancer Molecular Targets and Therapeutics

Ryan M. Finnegan
Ahmed M. Elshazly
Nipa H. Patel
Liliya Tyutyunyk-Massey
Tammy H. Tran
Vishnu Kumarasamy
Erik S. Knudsen
David A. Gewirtz

Frontiers in Oncology

doi 10.3389/fonc.2022.966441

4,749 views
19 citations

Original Research

Published on 16 Jan 2023

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients

in Cancer Molecular Targets and Therapeutics

Mohammad Aasif Khan
Sadaf
Irfan Ahmad
Abdulaziz A. Aloliqi
Alaa Abdulaziz Eisa
Mohammad Zeeshan Najm
Maria Habib
Saad Mustafa
Sheersh Massey
Zoya Malik

Frontiers in Oncology

doi 10.3389/fonc.2022.1078051

3,332 views
6 citations

Review

Published on 13 Jan 2023

Crosstalk between microwave ablation and ferroptosis: The next hot topic?

in Cancer Molecular Targets and Therapeutics

Lu Yu
Min Cheng
Jie Liu
Xin Ye
Zhigang Wei
Jiamei Xu
Qi Xie
Jing Liang

Frontiers in Oncology

doi 10.3389/fonc.2023.1099731

4,095 views
7 citations

Original Research

Published on 13 Jan 2023

Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors

in Cancer Molecular Targets and Therapeutics

Mohammad Amin Vaezi
Amir Reza Eghtedari
Banafsheh Safizadeh
Pegah Babaheidarian
Vahid Salimi
Fatemeh Adjaminezhad-Fard
Sahar Yarahmadi
Alireza Mirzaei
Mahtab Rahbar
Masoumeh Tavakoli-Yaraki

Frontiers in Oncology

doi 10.3389/fonc.2022.1096438

2,804 views
6 citations

Case Report

Published on 12 Jan 2023

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

in Cancer Molecular Targets and Therapeutics

Yuri Isaka
Akinori Sasaki
Akira Saito
Yasuaki Motomura
Yayoi Ando
Yoshiaki Nakamura

Frontiers in Oncology

doi 10.3389/fonc.2022.1064944

1,727 views
1 citation

Original Research

Published on 12 Jan 2023

Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients

in Cancer Molecular Targets and Therapeutics

Jie Cao
Kai Hong
Yuepeng Cao
Kenan Cen
Yifeng Mai
Ying Dai
Guifang Ouyang
Qitian Mu
Yangyang Guo

Frontiers in Oncology

doi 10.3389/fonc.2022.1096608

4,355 views
15 citations

Case Report

Published on 10 Jan 2023

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

in Cancer Molecular Targets and Therapeutics

Wen-Chi Wu
Ming-Huang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.1031396

2,080 views
1 citation

Review

Published on 10 Jan 2023

Potassium channels: Novel targets for tumor diagnosis and chemoresistance

in Cancer Molecular Targets and Therapeutics

Meizeng Li
Peijie Tian
Qing Zhao
Xialin Ma
Yunxiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1074469

6,338 views
27 citations